131 related articles for article (PubMed ID: 26805433)
1. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease.
Bhattacharyya S; Bakshi R; Logan R; Ascherio A; Macklin EA; Schwarzschild MA
Mov Disord; 2016 Mar; 31(3):417-21. PubMed ID: 26805433
[TBL] [Abstract][Full Text] [Related]
2. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.
Schwarzschild MA; Macklin EA; Bakshi R; Battacharyya S; Logan R; Espay AJ; Hung AY; Bwala G; Goetz CG; Russell DS; Goudreau JL; Parashos SA; Saint-Hilaire MH; Rudolph A; Hare JM; Curhan GC; Ascherio A;
Neurology; 2019 Oct; 93(14):e1328-e1338. PubMed ID: 31484712
[TBL] [Abstract][Full Text] [Related]
3. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
; Schwarzschild MA; Ascherio A; Casaceli C; Curhan GC; Fitzgerald R; Kamp C; Lungu C; Macklin EA; Marek K; Mozaffarian D; Oakes D; Rudolph A; Shoulson I; Videnovic A; Scott B; Gauger L; Aldred J; Bixby M; Ciccarello J; Gunzler SA; Henchcliffe C; Brodsky M; Keith K; Hauser RA; Goetz C; LeDoux MS; Hinson V; Kumar R; Espay AJ; Jimenez-Shahed J; Hunter C; Christine C; Daley A; Leehey M; de Marcaida JA; Friedman JH; Hung A; Bwala G; Litvan I; Simon DK; Simuni T; Poon C; Schiess MC; Chou K; Park A; Bhatti D; Peterson C; Criswell SR; Rosenthal L; Durphy J; Shill HA; Mehta SH; Ahmed A; Deik AF; Fang JY; Stover N; Zhang L; Dewey RB; Gerald A; Boyd JT; Houston E; Suski V; Mosovsky S; Cloud L; Shah BB; Saint-Hilaire M; James R; Zauber SE; Reich S; Shprecher D; Pahwa R; Langhammer A; LaFaver K; LeWitt PA; Kaminski P; Goudreau J; Russell D; Houghton DJ; Laroche A; Thomas K; McGraw M; Mari Z; Serrano C; Blindauer K; Rabin M; Kurlan R; Morgan JC; Soileau M; Ainslie M; Bodis-Wollner I; Schneider RB; Waters C; Ratel AS; Beck CA; Bolger P; Callahan KF; Crotty GF; Klements D; Kostrzebski M; McMahon GM; Pothier L; Waikar SS; Lang A; Mestre T
JAMA; 2021 Sep; 326(10):926-939. PubMed ID: 34519802
[TBL] [Abstract][Full Text] [Related]
4. Targeting urate to reduce oxidative stress in Parkinson disease.
Crotty GF; Ascherio A; Schwarzschild MA
Exp Neurol; 2017 Dec; 298(Pt B):210-224. PubMed ID: 28622913
[TBL] [Abstract][Full Text] [Related]
5. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
; Schwarzschild MA; Ascherio A; Beal MF; Cudkowicz ME; Curhan GC; Hare JM; Hooper DC; Kieburtz KD; Macklin EA; Oakes D; Rudolph A; Shoulson I; Tennis MK; Espay AJ; Gartner M; Hung A; Bwala G; Lenehan R; Encarnacion E; Ainslie M; Castillo R; Togasaki D; Barles G; Friedman JH; Niles L; Carter JH; Murray M; Goetz CG; Jaglin J; Ahmed A; Russell DS; Cotto C; Goudreau JL; Russell D; Parashos SA; Ede P; Saint-Hilaire MH; Thomas CA; James R; Stacy MA; Johnson J; Gauger L; Antonelle de Marcaida J; Thurlow S; Isaacson SH; Carvajal L; Rao J; Cook M; Hope-Porche C; McClurg L; Grasso DL; Logan R; Orme C; Ross T; Brocht AF; Constantinescu R; Sharma S; Venuto C; Weber J; Eaton K
JAMA Neurol; 2014 Feb; 71(2):141-50. PubMed ID: 24366103
[TBL] [Abstract][Full Text] [Related]
6. One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan.
Iwaki H; Ando R; Miyaue N; Tada S; Tsujii T; Yabe H; Nishikawa N; Nagai M; Nomoto M
J Neurol Sci; 2017 Dec; 383():75-78. PubMed ID: 29246629
[TBL] [Abstract][Full Text] [Related]
7. Uric acid in Parkinson's disease.
Schlesinger I; Schlesinger N
Mov Disord; 2008 Sep; 23(12):1653-7. PubMed ID: 18618666
[TBL] [Abstract][Full Text] [Related]
8. Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: changes linked to disease progression.
Ikeda K; Nakamura Y; Kiyozuka T; Aoyagi J; Hirayama T; Nagata R; Ito H; Iwamoto K; Murata K; Yoshii Y; Kawabe K; Iwasaki Y
Neurodegener Dis; 2011; 8(4):252-8. PubMed ID: 21282940
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide variant by serum urate interaction in Parkinson's disease.
Nazeri A; Roostaei T; Sadaghiani S; Chakravarty MM; Eberly S; Lang AE; Voineskos AN
Ann Neurol; 2015 Nov; 78(5):731-41. PubMed ID: 26284320
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis.
Walk D; Nicholson K; Locatelli E; Chan J; Macklin EA; Ferment V; Manousakis G; Chase M; Connolly M; Dagostino D; Hall M; Ostrow J; Pothier L; Lieberman C; Gelevski D; Randall R; Sherman AV; Steinhart E; Walker DG; Walker J; Yu H; Wills AM; Schwarzschild MA; Beukenhorst AL; Onnela JP; Berry JD; Cudkowicz ME; Paganoni S
Muscle Nerve; 2023 May; 67(5):378-386. PubMed ID: 36840949
[TBL] [Abstract][Full Text] [Related]
11. Inosine in Neurodegenerative Diseases: From the Bench to the Bedside.
Basile MS; Bramanti P; Mazzon E
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889517
[TBL] [Abstract][Full Text] [Related]
12. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease.
Chen X; Umeh CC; Tainsh RE; Feng DD; Maguire M; Zuo F; Rahimian M; Logan R; Wang X; Ascherio A; Macklin EA; Buys ES; Schwarzschild MA;
EBioMedicine; 2018 Nov; 37():259-268. PubMed ID: 30415890
[TBL] [Abstract][Full Text] [Related]
13. Urate as a predictor of the rate of clinical decline in Parkinson disease.
Ascherio A; LeWitt PA; Xu K; Eberly S; Watts A; Matson WR; Marras C; Kieburtz K; Rudolph A; Bogdanov MB; Schwid SR; Tennis M; Tanner CM; Beal MF; Lang AE; Oakes D; Fahn S; Shoulson I; Schwarzschild MA;
Arch Neurol; 2009 Dec; 66(12):1460-8. PubMed ID: 19822770
[TBL] [Abstract][Full Text] [Related]
14. Urate as a Marker of Risk and Progression of Neurodegenerative Disease.
Paganoni S; Schwarzschild MA
Neurotherapeutics; 2017 Jan; 14(1):148-153. PubMed ID: 27995438
[TBL] [Abstract][Full Text] [Related]
15. Effect of pharmacological lowering of plasma urate on exercise-induced oxidative stress.
McAnulty SR; Hosick PA; McAnulty LS; Quindry JC; Still L; Hudson MB; Dibarnardi AN; Milne GL; Morrow JD; Austin MD
Appl Physiol Nutr Metab; 2007 Dec; 32(6):1148-55. PubMed ID: 18059589
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action.
Zhu TG; Wang XX; Luo WF; Zhang QL; Huang TT; Xu XS; Liu CF
Neurosci Lett; 2012 Jan; 506(2):175-9. PubMed ID: 22094380
[TBL] [Abstract][Full Text] [Related]
17. Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude.
Baillie JK; Bates MG; Thompson AA; Waring WS; Partridge RW; Schnopp MF; Simpson A; Gulliver-Sloan F; Maxwell SR; Webb DJ
Chest; 2007 May; 131(5):1473-8. PubMed ID: 17494796
[TBL] [Abstract][Full Text] [Related]
18. Urate as a marker of development and progression in Parkinson's disease.
Constantinescu R; Zetterberg H
Drugs Today (Barc); 2011 May; 47(5):369-80. PubMed ID: 22013567
[TBL] [Abstract][Full Text] [Related]
19. Serum urate and the risk of Parkinson's disease: results from a meta-analysis.
Shen C; Guo Y; Luo W; Lin C; Ding M
Can J Neurol Sci; 2013 Jan; 40(1):73-9. PubMed ID: 23250131
[TBL] [Abstract][Full Text] [Related]
20. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.
Gonsette RE; Sindic C; D'hooghe MB; De Deyn PP; Medaer R; Michotte A; Seeldrayers P; Guillaume D;
Mult Scler; 2010 Apr; 16(4):455-62. PubMed ID: 20200198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
